Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
The last time we had an upward run on the shares the Company issued an RNS saying de facto that they knew no reason why the shares were moving up in the market given there was no firm deal in place and there was a very real risk of crashing out of AIM if a buyer for assets where not found soon. This was issued at 1.21pm, on the day, during market trading.
As I type there has been no such RNS today which is strange if in fact there is nothing of note going on other than the change to the BOD. This begs the question, why no RNS today?
Interesting and even more interesting if no RNS appears to this effect before trading starts tomorrow.
AIMHO
If it’s going to crash and burn why change the Board? Doesn’t mean s/h won’t be screwed over but the change is for a reason as is the lack of a speeding ticket RNS
If its not issued on the day of the rise speeding tickets are NOT issued.
Research and speculation, is Motif going to be left to go into oblivion, or has the appointment of Lamellar's Director to the Motif BoD increased the chances of a successful RTO....Motif's current market cap after today's stellar rise is still only £7m , and so what market cap would Lamellar have on RTO, and then what value again on confirmation of Covid-19 patinent trials thereafter using their nebuliser inhaler technology in combination with Motifs ilcaprim. £10's of millions at the very least....Gla holders....Fortune favours the brave.;-)
Moneymunch I was just typing a similar post. But you got there first. Better anyway. Agree
Moneymunch...thank u for your feedback
Cheers mazik and eviking, let's hope for more of the same tomorrow, i really don't think that the highly respectable and high profile Director of Lamellar would have joined Motif's BoD at this stage in proceedings if he wasn't confident of a positive outcome. Lamellar and Motif have been in collaboration since May 2019 in evaluating iclaprim in combination with Lamellar's patented LAMELLASOME(TM) technology, the companies believe that, based on pre-clinical data with the two individual components, the combination could be a promising potential treatment for lung infections in patients with CF.
https://uk.advfn.com/p.php?pid=nmona&article=79804720&symbol=LSE%3AMTFB
Has this just got 7 bagged with restructuring of management? Doesn't make sense.
Am I missing something here?
ps and of course since last years collaboration , Lamellar have now confirmed extremly positive potential for Covid-19 treatmnent. Gl ;-)
8/4/20
Lamellar Biomedical Launches Program Designed to Prevent the Severe Respiratory Effects of COVID-19, Using its Unique LAMELLASOMEâ„¢ Technology
....................
A LAMELLASOMEâ„¢ nebulised treatment used at the early stages of COVID-19, in hospital or the community, could reduce the damaging and often fatal inflammatory response known as Acute Respiratory Distress Syndrome (ARDS) seen in patients. This early intervention has the potential to inhibit fibroproliferative changes during ARDS, markedly reducing severity, mortality and lowering the significant burden placed on the healthcare system.
The time between onset of symptoms of SARS-CoV2 infection and progression to more severe clinical manifestations of COVID-19 such as viral pneumonia and ARDS, is thought to be between 5 – 8 days. Inhaled LAMELLASOME™ treatment administered during this period has the potential to halt or reduce the severity of the disease progression of COVID-19 patients to requiring scarce critical care resource.
Lamellar has strong pre-clinical evidence of inhaled LAMELLASOME™'s protective nature. In a large animal in‑vivo model of radiation-induced lung injury, designed to replicate the pathology found in the injured lung, which is representative of COVID-19 patient pathology, inhaled LAMELLASOME™ treatment protected lung cells and tissues from injury, pneumonitis and fibroproliferation/fibrosis at the alveolar/capillary membrane.
Dr Duncan Moore, Chairman of Lamellar, said: "In the past few weeks we have seen the terrible consequences COVID-19 can have on the respiratory function, particularly on vulnerable patient populations. We believe that that the inherent attributes of LAMELLASOMEâ„¢ are extremely well suited to be a potential approach to preventing the onset of the serious respiratory symptoms seen in COVID-19 patients. Lamellar is focused on treating complex lung disorders and we believe that our Lamellasome formulations could make an important difference to patients and healthcare providers globally."
Dr Nik Hirani, Reader in Respiratory Medicine and Associate Medical Director in Lothian and Former chair of NICE Thoracic Interstitial Lung Disease guideline committee, said: "Lamellar has very convincing data demonstrating strong in-vivo efficacy for Lamellasome formulations in a model relevant to pneumonitis, lung injury and ARDS. I have been following the development of LAMELLASOMEâ„¢ technology and its development as a respiratory therapeutic over the past few years, and I believe it has real potential to manage the inflammatory respiratory symptoms seen in patients infected with SARS-CoV2."
hTtps://www.ptcommunity.com/wire/lamellar-biomedical-launches-program-designed-prevent-severe-respiratory-effects-covid-19-using
Its shares in US stock exchange are in red today
MONEYMUNCH CHEERS YOUR GOOD REALLY GOOD
In the red on the Nasdaq you say? That's even more remarkable considering its already been delisted over there.
Try again.
Correct, it is not live price on Nasdaq. My bad, I was searching for MTFB on IG app and found Nasdaq one instead of LON listing.
Missthepenny thanks all in the rns to see. Delisted on the nas
Lol, cheers eviking, research and speculation, fingers firmly crossed for a positive outcome. Gl ;-)
People make a company, simple as that. Board appointments or firings can effect some companies to the tune of hundreds of millions. Imagine if Bezos left Amazon, that would lose a few billion on the same day.